Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DKP21102_B
- Development stage
- Discontinued
- Lead developer
- Dongkwang Pharm
01
Overview
DKP21102_B is an investigational pharmaceutical agent developed by Dongkwang Pharm. Co., Ltd. for the treatment of mixed dyslipidemia, specifically in patients whose low-density lipoprotein cholesterol (LDL-C) is adequately controlled but who continue to have elevated triglyceride and/or low high-density lipoprotein cholesterol (HDL-C) levels despite treatment with DKP21102_A. The drug was studied as an add-on therapy to DKP21102_A in a Phase 3 clinical trial, which was ultimately withdrawn before completion. The precise mechanism of action, molecular modality, and active ingredients of DKP21102_B have not been publicly disclosed as of June 2025[1][2][4].
- Other names
- DKP21102_B
Beyond the preview
Go deeper on DKP21102_B.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DKP21102_B.